Literature DB >> 574040

The oral activity of delta'-tetrahydrocannabinol and its dependence on prostaglandin E2.

J W Fairbairn, J T Pickens.   

Abstract

1 delta'-trans-Tetrahydrocannabinol (THC) is more active orally in mice than previously thought, as cataleptic responses occur at doses from 0.06 mg/kg upwards, with peak activity at 2 to 4 h after dosing. These doses and peaks correspond well with the effects in man. 2 Comparison with chlorpromazine in mice shows that chlorpromazine and THC are equipotent as cataleptics during the first 2 h after dosing; thereafter the THC activity increases to a peak when it is 5.67 times as active as chlorpromazine. 3 The cataleptic effect of THC is abolished by aspirin, indomethacine, diffunisal and phenylbutazone which inhibit the biosynthesis of prostaglandins and is restored by exogenous prostaglandin E2 (PGE2) but not PGE1 and PGF2 alpha. This suggests that the effect of THC depends upon the presence of PGE2. 4 In contrast, the cataleptic effect of chlorpromazine is not affected by pretreatment with aspirin. 5 THC is very much less active intraperitoneally than orally; our results suggest this is not due to poor absorption or extraction into fat depots. 6 Cannabidiol has no cataleptic effect.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 574040      PMCID: PMC2043943          DOI: 10.1111/j.1476-5381.1979.tb08691.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  The effect of delta9-tetrahydrocannabinol on plasma concentrations of non-esterified fatty acids in the mouse.

Authors:  R Malor; G B Chesher; D M Jackson
Journal:  J Pharm Pharmacol       Date:  1976-08       Impact factor: 3.765

2.  Pharmacology and toxicology of diflunisal.

Authors:  C A Stone; C G Van Arman; V J Lotti; D H Minsker; E A Risley; W J Bagdon; D L Bokelman; R D Jensen; B Mendlowski; C L Tate; H M Peck; R E Zwickley; S E McKinney
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

3.  Discovery of diflunisal.

Authors:  J Hannah; W V Ruyle; H Jones; A R Matzuk; K W Kelly; B E Witzel; W J Holtz; R W Houser; T Y Shen; L H Sarett
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

4.  Marihuana: importance of the route of administration.

Authors:  B T Ho; G E Fritchie; L F Englert; W M McIsaac; J E Idänpään-Heikkilä
Journal:  J Pharm Pharmacol       Date:  1971-04       Impact factor: 3.765

5.  Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs.

Authors:  P J Piper; J R Vane
Journal:  Nature       Date:  1969-07-05       Impact factor: 49.962

6.  Effects of (--)delta-9-trans-tetrahydrocannabinol in man.

Authors:  H Isbell; C W Gorodetzsky; D Jasinski; U Claussen; F von Spulak; F Korte
Journal:  Psychopharmacologia       Date:  1967

7.  Pharmacology of orally administered 9 -tetrahydrocannabinol.

Authors:  M Perez-Reyes; M A Lipton; M C Timmons; M E Wall; D R Brine; K H Davis
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

8.  Storage of cannabinoids by Arctia caja and Zonocerus elegans fed on chemically distinct strains of Cannabis sativa.

Authors:  M Rothschild; M G Rowan; J W Fairbairn
Journal:  Nature       Date:  1977-04-14       Impact factor: 49.962

Review 9.  Dose-response relationships to cannabis in human subjects.

Authors:  G F Kiplinger; J E Manno
Journal:  Pharmacol Rev       Date:  1971-12       Impact factor: 25.468

10.  Comparative effects of aspirin and diflunisal on prostaglandin synthetase from human platelets and sheep seminal vesicles.

Authors:  P W Majerus; N Stanford
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

View more
  8 in total

1.  Effects of cannabidiol in animal models predictive of antipsychotic activity.

Authors:  A W Zuardi; J A Rodrigues; J M Cunha
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  The effect of conditions influencing endogenous prostaglandins on the activity of delta'-tetrahydrocannabinol in mice.

Authors:  J W Fairbairn; J T Pickens
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

3.  A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice.

Authors:  S Burstein; S A Hunter; V Latham; L Renzulli
Journal:  Experientia       Date:  1987-04-15

4.  delta-9-tetrahydrocannabinol (THC) increases brain prostaglandins in the rat.

Authors:  S K Bhattacharya
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Alteration in the level of endogenous hypothalamic prostaglandins induced by delta 9-tetrahydrocannabinol in the rat.

Authors:  I M Coupar; D A Taylor
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

6.  Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling.

Authors:  Rongqing Chen; Jian Zhang; Ni Fan; Zhao-Qian Teng; Yan Wu; Hongwei Yang; Ya-Ping Tang; Hao Sun; Yunping Song; Chu Chen
Journal:  Cell       Date:  2013-11-21       Impact factor: 41.582

7.  Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content.

Authors:  J T Pickens
Journal:  Br J Pharmacol       Date:  1981-04       Impact factor: 8.739

8.  Activity of cannabis in relation to its delta'-trans-tetrahydro-cannabinol content.

Authors:  J W Fairbairn; J T Pickens
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.